# China NMPA Drug Inspection - Anhui Yishengyuan Traditional Chinese Medicine Pieces Technology Co., Ltd. - Stir-fried Atractylodes lancea

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/anhui-yishengyuan-traditional-chinese-medicine-pieces-technology-co-ltd/04f47c76-8724-4bbd-a649-96b1807a24c4/
Source feed: China

> China NMPA drug inspection for Anhui Yishengyuan Traditional Chinese Medicine Pieces Technology Co., Ltd. published May 30, 2018. Drug: Stir-fried Atractylodes lancea. This announcement from the Henan Provincial Food and Drug Administration, dated May 30, 2018, details findings of substa

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement from the Henan Provincial Food and Drug Administration Regarding Three Batches of Substandard Drugs (Issue No. 5, 2018)
- Company Name: Anhui Yishengyuan Traditional Chinese Medicine Pieces Technology Co., Ltd.
- Publication Date: 2018-05-30
- Drug Name: Stir-fried Atractylodes lancea
- Inspection Finding: Content does not meet regulations
- Action Taken: Relevant food and drug regulatory authorities are required to take necessary risk control measures such as sealing up, seizing, and suspending the sale of substandard drugs found in random inspections, and to investigate and punish the units that source the samples in accordance with the law.
- Summary: This announcement from the Henan Provincial Food and Drug Administration, dated May 30, 2018, details findings of substandard drugs from two manufacturers following regulatory testing. The review identified issues across three batches of traditional Chinese medicine. Anhui Yiyuantang Traditional Chinese Medicine Pieces Technology Co., Ltd. was cited for two batches of "Stir-fried Atractylodes lancea"; batch 170420 was non-compliant due to moisture content, and batch 170401 failed to meet specifications for its general content. Separately, Anhui Jiayou Traditional Chinese Medicine Pieces Co., Ltd. had a batch of "Acanthopanax senticosus" (170803) deemed substandard due to issues with its extractive properties. These evaluations were conducted by provincial drug inspection agencies, including the Luoyang Municipal Food and Drug Inspection Institute and Xuchang Municipal Food and Drug Inspection and Testing Center, against the standards outlined in the Chinese Pharmacopoeia 2015 Edition, Part I. In response, the Henan Provincial Food and Drug Administration has mandated immediate corrective actions, instructing relevant departments to implement risk control measures such as sealing, seizure, and suspending sales for the identified substandard drugs. Furthermore, legal investigations and penalties are to be pursued against the responsible companies.

Company: https://www.globalkeysolutions.net/companies/anhui-yishengyuan-traditional-chinese-medicine-pieces-technology-co-ltd/c2292c5b-5423-41d2-824e-557e75208bc9/